PPARA and neoplasm: Metabolomic study indicated that inhibition of PAFAH1B3 suppressed the growth of breast cancer by upregulating the levels of anti-tumor lipids, such as ceramides and several PPARα ligands, indicating that PAFAH1B3 serves as a metabolic oncogene in breast cancer (10).